Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study

  1. Mateos, M.-V.
  2. Orlowski, R.Z.
  3. Ocio, E.M.
  4. Rodríguez-Otero, P.
  5. Reece, D.
  6. Moreau, P.
  7. Munshi, N.
  8. Avigan, D.E.
  9. Siegel, D.S.
  10. Ghori, R.
  11. Farooqui, M.Z.H.
  12. Marinello, P.
  13. San-Miguel, J.
Revue:
British Journal of Haematology

ISSN: 1365-2141,  0007-1048

Année de publication: 2019

Volumen: 186

Número: 5

Pages: e117-e121

Type: Lettre

DOI: 10.1111/BJH.15946 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus